Metabolic Syndrome Lab Report

INTRODUCTION

Metabolic syndrome (syndrome X, insulin resistance syndrome) consists of constellation of metabolic abnormalities which include central obesity, hyperglycemia plus insulin resistance, high triglycerides plus low HDL cholesterol, and hypertension.1

NCEP:ATP III 2001 Criteria for the Metabolic Syndrome2 :-

Three or more of the following:

. Central obesity: Waist circumference ≥102 cm in males or ≥ 88 cm in females

.Hypertriglyceridemia: triglycerides ≥ 150mg/dl

.Low HDL cholesterol < 40 mg/dL (males) or < 50 mg/dL (females)

.Hypertension: blood pressure ≥ 130mm systolic or ≥85mm diastolic

.Fasting plasma glucose ≥100mg/dl.

Prevalence of Metabolic syndrome is increasing all over the world with different regions having individual

Frequency of subclinical thyroid dysfunction and risk fac¬tors for cardiovascular disease among women at a workplace. Sao Paulo Med J 2010;128:18-23. Bhowmick SK, Dasari G, Levens KL, Rettig KR. The prevalence ofelevated serum thyroid-stimulating hormone in childhood/adolescentobesity and of autoimmune thyroid diseases in a subgroup. J NatlMed Assoc 2007;99:773-6 .Liu YY, Brent GA. Thyroid hormone crosstalk with nuclear re¬ceptor signaling in metabolic regulation. Trends EndocrinolMetab 2010;21:166-73. Agarwal G, Sudhakar MK, Singh M, Senthil N, Rajendran A. The prevalence of thyroid dysfunction among south Indian women with metabolic syndrome. J ClinDiagn Res 2011;5:213-6. Shantha GP, Kumar AA, Jeyachandran V, Rajamanickam D, Ra¬jkumar K, Salim S, Subramanian KK, Natesan S. Association be¬tween primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India. Thyroid Res 2009;2:2 Walsh JP, Brenner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165:

MedClin North Am 1985, 69:849. Serter R, Demirbas B, Culha C, Cakal E: The effect of L-thyroxinereplacement therapy on lipid based cardiovascular risk insub clinical hypothyroidism. Invest J Endocrinol2004, 27:897-903 .Waring AC, Rodondi N, Harrison S, Kanaya AM, SimonsickEM,Miljkovic I, Satterfield S, Newman AB & Bauer DC. Thyroidfunction and prevalent and incident metabolic syndrome in olderadults: the Health, Ageing and Body Composition Study. ClinicalEndocrinology 2012 76 911–918. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, MakriMG, et al. Thyroid Function in Humans with Morbid Obesity. Thyroid 2006;16:73-8 Bastemir M, Akin F, Alkis E, Kaptanoglu B. Obesity is associated with increased serum TSH level, independent of thyroid function. Swiss Med wkly 2007;137:431-4. Tagliaferri M, Berselli ME, CalòG, Minocci A, Savia G, Petroni ML, etal.Subclinical hypothyroidism in obese patients: Relation to resting energy expenditure, serum leptin, body composition, and lipid profile. Obes Res 2001;9:196-201. Kundsen N, Lamberg P, Rasmussen LB, Bulow I, Perrild H, Ovessen L et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J ClinEndocrinolMetab